We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current AGN market cap is 87.81M. The company's latest EPS is AUD -0.0446 and P/E is -15.92.
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 0 | 296k | 259k | 1.75M | 2.6M |
| Operating Income | 0 | -614k | -4.09M | -4.88M | -5.67M |
| Net Income | 0 | -1.03M | -4.09M | -4.82M | -5.48M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 7.52M | 7.27M | 9.04M | 9.54M | 16.38M |
| Total Liabilities | 58k | 426k | 736k | 1.87M | 2.43M |
| Total Equity | 7.46M | 6.85M | 8.31M | 7.67M | 13.95M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | N/A | -1.05M | -3.36M | -3.3M | -5.06M |
| Investing | N/A | N/A | N/A | -50k | 50k |
| Financing | N/A | 7.85M | 5.13M | 3.73M | 11.64M |
| Market Cap | 87.81M |
| Price to Earnings Ratio | -15.92 |
| Price to Sales Ratio | 33.49 |
| Price to Cash Ratio | 5.48 |
| Price to Book Ratio | 6.25 |
| Dividend Yield | - |
| Shares Outstanding | 122.82M |
| Average Volume (1 week) | 155.3k |
| Average Volume (1 Month) | 150.41k |
| 52 Week Change | 60.67% |
| 52 Week High | 0.985 |
| 52 Week Low | 0.415 |
| Spread (Intraday) | 0.03 (4.05%) |
| Company Name | Argenica Therapeutics Limited |
| Address |
unit 4 nedlands, western australia 6009 |
| Website | https:// |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
